RPTX
Repare Therapeutics Inc

1,026
Mkt Cap
$114.24M
Volume
1.22M
52W High
$2.66
52W Low
$0.89
PE Ratio
-1.56
RPTX Fundamentals
Price
$2.65
Prev Close
$2.63
Open
$2.64
50D MA
$2.43
Beta
1.02
Avg. Volume
924,219.75
EPS (Annual)
-$2.00
P/B
0.99
Rev/Employee
$414,550.39
$95.30
Loading...
Loading...
News
all
press releases
Repare Therapeutics Inc. (NASDAQ:RPTX) Short Interest Up 125.3% in January
Repare Therapeutics Inc. (NASDAQ:RPTX - Get Free Report) saw a large increase in short interest during the month of January. As of January 15th, there was short interest totaling 437,896 shares, an...
MarketBeat·16d ago
News Placeholder
More News
News Placeholder
Repare Shareholders Approve Acquisition by XenoTherapeutics, Inc.
Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced that its Shareholders (as defined below) have approved the acquisition of...
Business Wire·29d ago
News Placeholder
Repare Therapeutics Inc. (NASDAQ:RPTX) Short Interest Update
Repare Therapeutics Inc. (NASDAQ:RPTX - Get Free Report) saw a large decrease in short interest during the month of December. As of December 31st, there was short interest totaling 194,336 shares, a...
MarketBeat·1mo ago
News Placeholder
Repare Therapeutics (NASDAQ:RPTX) Stock Price Up 0.4% - Here's Why
Repare Therapeutics (NASDAQ:RPTX) Shares Up 0.4% - Still a Buy...
MarketBeat·1mo ago
News Placeholder
Repare Therapeutics Sees Unusually Large Options Volume (NASDAQ:RPTX)
Repare Therapeutics Inc. (NASDAQ:RPTX - Get Free Report) saw some unusual options trading on Wednesday. Stock investors bought 3,187 call options on the company. This represents an increase of 407...
MarketBeat·2mo ago
News Placeholder
Repare Therapeutics Stock Rises As Gilead Secures Cancer Asset For $30 Million
Gilead agreed to acquire Repare's RP-3467 cancer drug for up to $30 million, boosting Repare's cash and expected shareholder payout.read more...
Benzinga·2mo ago
News Placeholder
RPTX Stock Soars Pre-Market After Gilead Agrees To Acquire Investigational Cancer Drug
Repare stated that Gilead has agreed to acquire polymerase theta (Polθ) ATPase inhibitor, RP-3467, for a total consideration of $30 million.
Stocktwits·2mo ago
News Placeholder
Repare Therapeutics Announces Acquisition of Pol ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration
Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced a definitive asset purchase agreement for Gilead Sciences, Inc. to...
Business Wire·2mo ago
News Placeholder
Halper Sadeh LLC Encourages UBFO, CWBC, RPTX Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC Encourages UBFO, CWBC, RPTX Shareholders to Contact the Firm to Discuss Their Rights Halper Sadeh LLC Encourages UBFO, CWBC, RPTX Shareholders to Contact the Firm to Discuss Their...
PR Newswire·2mo ago
News Placeholder
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--RPTX, FRGE, CSGS, FIZN
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--RPTX, FRGE, CSGS, FIZN $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--RPTX, FRGE...
PR Newswire·2mo ago
<
1
2
...
>

Latest RPTX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.